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Alternative splicing of dystrobrevin regulates the stoichiometry
of syntrophin binding to the dystrophin protein complex
Sarah E. Newey*, Matthew A. Benson*, Chris P. Ponting†, Kay E. Davies†
and Derek J. Blake*
Dystrophin coordinates the assembly of a complex of
structural and signalling proteins that is required for
normal muscle function. A key component of the
dystrophin-associated protein complex (DPC) is
α-dystrobrevin, a dystrophin-related and -associated
protein whose absence results in muscular dystrophy
and neuromuscular junction defects [1,2]. The current
model of the DPC predicts that dystrophin and
dystrobrevin each bind a single syntrophin molecule
[3]. The syntrophins are PDZ-domain-containing
proteins that facilitate the recruitment of signalling
proteins such as nNOS (neuronal nitric oxide synthase)
to the DPC [4]. Here we show, using yeast two-hybrid
analysis and biochemical binding studies, that
α-dystrobrevin in fact contains two independent
syntrophin-binding sites in tandem. The previously
undescribed binding site is situated within an
alternatively spliced exon of α-dystrobrevin, termed the
variable region-3 (vr3) sequence, which is specifically
expressed in skeletal and cardiac muscle [5,6]. Analysis
of the syntrophin-binding region of dystrobrevin
reveals a tandem pair of predicted α helices with
significant sequence similarity. These α helices, each
termed a syntrophin-binding motif, are also highly
conserved in dystrophin and utrophin. Together these
data show that there are four potential syntrophin-
binding sites per dystrophin complex in skeletal
muscle: two on dystrobrevin and two on dystrophin or
utrophin. Furthermore, alternative splicing of
dystrobrevin provides a mechanism for regulating the
stoichiometry of syntrophin association with the DPC.
This is likely to have important consequences for the
recruitment of specific signalling molecules to the DPC
and ultimately for its function.
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Results and discussion
Alternative splicing of the α-dystrobrevin gene in skeletal
and cardiac muscle generates three isoforms (α-dystro-
brevin-1, -2 and -3) of which only the two larger isoforms
α1 and α2 contain the syntrophin- and dystrophin-binding
sites [6] (Figure 1a). α-Dystrobrevin-1 and -2 are also
subject to further alternative splicing in skeletal and cardiac
muscle, resulting in the expression of two additional exons
before the coiled-coil domain. The function of these addi-
tional 57 amino acids, termed the vr3 sequence in mouse,
has not been described (Figure 1a).
To identify binding partners for the vr3 sequence of
α-dystrobrevin, a yeast two-hybrid screen was performed
using the alternatively spliced exons 12 and 13 as a ‘bait’
(Figure 1a). This vr3 bait, which also contained 16
residues of common α-dystrobrevin flanking sequence,
was screened against a cDNA library generated from cul-
tured H2K myotubes. Approximately 3 million clones
were screened and of the 28 vr3 interactors identified, 18
clones encoded β1-syntrophin and 6 encoded α-syntrophin.
This implies that the vr3 sequence binds syntrophin.
Biochemical and yeast two-hybrid studies have previously
been published with the aim of defining the syntrophin-
binding site on dystrobrevin and dystrophin [7–11].
Although there were some discrepancies, these reports all
argued that the syntrophin-binding site was located
upstream of the first coiled-coil domain of both dystro-
brevin and dystrophin (Figure 1a). Thus, the data from
our yeast two-hybrid screen indicates that the vr3 sequence
provides a second syntrophin-binding site in skeletal and
cardiac muscle.
To test the hypothesis that the vr3 sequence provides a
second syntrophin-binding site on α-dystrobrevin, we
generated a series of new α-dystrobrevin bait constructs
and tested their ability to interact with α and β1 syn-
trophins in the yeast two-hybrid system (Figure 1a). The
vr3 sequence was separated into its constituent exons 12
and 13, and a new vr3 bait was generated that did not
contain any common α-dystrobrevin flanking sequence
(exons 12 + 13, Figure 1a). Finally, we constructed a bait
encompassing the previously characterised syntrophin-
binding site of exon 14 together with the first coiled-coil
domain (exon 14 + cc1, Figure 1a). Co-transformed yeast
were tested for expression of β-galactosidase and growth
on histidine-deficient media. As Figure 1b illustrates,
exon 12 of the vr3 sequence does not interact with either
of the syntrophins, whereas both exon 13 and exon 14 + ccI
baits clearly interact, thus confirming the existence of two
distinct syntrophin-binding sites on α-dystrobrevin. 
Sequence analysis of the syntrophin-binding region of
α-dystrobrevin identifies a previously undescribed tandem
pair of predicted α helices, one in the vr3 exon 13 and the
other in exon 14. These α helices are similar to each other
and each helix is predicted to form a syntrophin-binding
motif. These tandem helices are not only found in α-dys-
trobrevin, but also in the other members of the dystrophin
family of proteins, including utrophin (Figure 2). The
sequence similarity between the pair of tandem syntro-
phin-binding motifs is most apparent for β-dystrobrevin
[12,13]. Self-comparison of human β-dystrobrevin
(GenBank identifier 2935183) using MACAW [14] and
PROSPERO [15] revealed significant sequence similar-
ity (p = 1.4 × 10–4 and 5.6 × 10–6, for the two methods
respectively) between the two repeats. As the dystro-
brevins, dystrophins and utrophins can be aligned accu-
rately throughout their carboxy-terminal regions, it can be
inferred from the pair of sequence-similar motifs in dys-
trobrevins that all other dystrophin-related molecules also
possess such syntrophin-binding sites. The exception is
the sequence of C. elegans DYS-1, for which no syntrophin-
binding motif repeats could be found. In summary, the
skeletal muscle DPC has four syntrophin-binding motifs:
two located in α-dystrobrevin and two in dystrophin.
To confirm that the predicted syntrophin-binding motif of
dystrobrevin is able to bind syntrophin, a minimal peptide
encompassing this region was synthesised and chemically
linked to an affinity matrix. The immobilised peptide was
incubated with mouse brain or skeletal muscle extracts
and the bound proteins were eluted. As Figure 3 shows,
western blots of these eluates demonstrated the specific
binding of syntrophin to the syntrophin-binding motif
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Figure 1
(a) Schematic representation of the α-dystrobrevin isoforms in muscle.
The identifiable domains are boxed: EF, EF hand region, predicted
calcium-binding domain; ZZ, ZZ domain, putative zinc-binding domain;
vr3, variable region 3; cc, coiled-coil domain [23]; Y, unique tyrosine
kinase substrate domain of α-dystrobrevin-1. The location of the
previously identified dystrophin-binding site (DBS) [23,24] and
syntrophin-binding site (SBS) [7-11] are indicated by blue lines. The
red lines indicate the yeast two-hybrid bait constructs generated for
defining the syntrophin-binding sites on α-dystrobrevin. (b) Evidence
for two syntrophin-binding sites on α-dystrobrevin in skeletal and
cardiac muscle. β-Galactosidase filter assays were performed on yeast
co-transformed with the bait and prey constructs indicated. All baits
were co-transformed with the empty prey vector pYesTrp2 to confirm
that these constructs do not nonspecifically activate the lacZ and HIS3
reporter genes. Exon 12 of the vr3 sequence does not interact with
α1- or β1-syntrophin preys as indicated by the pink yeast. Vr3 exon 13
and exon 14 + cc1 baits both interact with syntrophin as shown by the
production of β-galactosidase. Negative controls: empty bait vector
(pHybLex/Zeo) co-transformed with empty prey vector (pYesTrp2).
Positive control: full-length β-dystrobrevin bait in pHybLex/Zeo co-
transformed with α1-syntrophin prey in pYesTrp2 (M.A.B. and D.J.B.,
unpublished results).
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Figure 2
A multiple sequence alignment of the tandem syntrophin-binding motifs,
coloured using CHROMA (http://www.lg.ndirect.co.uk/chroma/) and a
consensus sequence calculated at a 75% level. Aliphatic (l) residues or
big (b) residues are grey on yellow; hydrophobic (h) residues black on
yellow; polar (p) residues blue; small (s) residues dark green; tiny (t)
residues in light green; negatively charged (–) residues in red; and amino
acids conserved in >75% of sequences are yellow on black. Aster,
Asteroidea (starfish); DMD, Duchenne muscular dystrophy gene product;
DROME, Drosophila melanogaster; Dysb, dystrobrevin; DysL, dystrophin-
like; Dysr, dystrophin-related; Gobsp, Gobius sp.; PECTI, Pectinidae
(scallops); SCYCA, Scyliorhinus canicula (smaller spotted catshark);
STRPU, Strongylocentrotus purpuratus; TORCA, Torpedo californica;
XENLA, Xenopus laevis; UTRO, utrophin.
αDysb_MOUSE     ADRLADEHVLIGLYVNMLRNNP------PCMLES
βDysb_HUMAN     PSHLADEHALIASYVARLQHCA-------RVLDS
Dysr2_MOUSE     MLPHADTHSRIEHFASRLAEMESQN(4)NDSLSP
Dysr2_Gobsp     RLPHADTHSRIEHYASRLAEMESQN(4)TDSLSP
Dysr2_SCYCA     MLPHADTHSRIEHYASRLAEMESKN(4)SGSLSP
DMD_MOUSE       QLSHDDTHSRIEHYASRLAEMENSN(4)NDSISP
DMD_TORCA       QLSHDDTHSRIEHYLSRLAEMENRN(4)NDSISP
DMD_DROME       HQLQNDMHSRLEMYASRLAQVEYGG----TGSNS
DMD_CIOIN       NGGANETHEKIEEYARILADLD-------DETGV
UTRO_MOUSE      QLFHDDTHSRIEQYATRLAQMERTN(4)TDSSST
UTRO_SCYCA      QLSQDDTHSRIEHYANRLAQMERTN(4)TDSSST
UTRO_XENLA      ELLHDDTHSRIEQYASRLAQMERTN(4)TDNSSA
SuDp98_STRPU    HMANQDTHTRLELYANRLAEVESQG----TLNSV
DysL_Aster      QMANEDMHTRLELYASRLAEVEEHG----SFLTP
DysL_BRALA      QAVSQDMHSRLELYASRLAEVEQSM----NSMSS
DysL_PECTI      SISSQDMHSRLELYANRLAEVEQR------QASS
Consensus/75%   pb.psDpHtRlEbYAsRLAphEpp.....s..ts
2-structure            hhhHHHHHHHHHHHHHH
αDysb_MOUSE     SNRLDEEHRLIARYAARLAAES
βDysb_HUMAN     PSRLDEEHRLIARYAARLAAEA
Dysr2_MOUSE     DDSIDEDQYLLRHSSPITDREP
Dysr2_Gobsp     DESLDEDQYLLRHSSPALEPDS
Dysr2_SCYCA     DESVDDEQLIVQYFSPETDQDS
DMD_MOUSE       NESIDDEHLLIQHYCQSLNQDS
DMD_TORCA       NESIDDEHLLIQHYCQSLNQES
DMD_DROME       TPDSDDEHQLIAQYCQALPGTS
DMD_CIOIN       QAPLDEEQECILEYRGALTEDK
UTRO_MOUSE      TGSVEDEHALIQQYCQTLGGES
UTRO_SCYCA      TGSVEDEHILIQQYCLTLGRES
UTRO_XENLA      TGSMEDEHALIQQFCHTLGGDS
SuDp98_STRPU    PTDLEDEHQLIAHYCHSLGGDV
DysL_Aster      SPDLDDEHQLIAQYCQSLGGDV
DysL_BRALA      SSDMEDEHTLIQQYCQSLGGDS
DysL_PECTI      TPDSDDEHNLIAQYCQSLNGNT
Consensus/75%   sssl--EHbLI.pYs.sLs.-s
2-structure         hHHHHHHHHHHHH Current Biology   
peptide (SBM-PEP), but not to a control dystrobrevin
peptide (DB-PEP), nor to the affinity matrix (NO-PEP).
This confirms the physiological relevance of the predicted
dystrobrevin–syntrophin interaction.
Since the pioneering identification of dystrophin, an
extensive literature has accumulated on the function and
binding partners of this protein (for review, see [16,17]).
Despite this wealth of knowledge, very little is known
about the mechanisms and sequences that are required for
building the DPC. The present study not only provides
the sequence basis for syntrophin binding to the DPC but
also shows that alternative splicing offers a mechanism for
regulating the number of syntrophin-binding sites within
a given complex.
Alternative splicing is not only used by α-dystrobrevin to
regulate the stoichiometry of syntrophin binding. Dys-
trophin is also alternatively spliced in the syntrophin-
binding region in brain, heart and skeletal muscle,
generating further flexibility in the number of syntrophin
molecules that can associate with the DPC [18,19]. Alter-
native splicing of dystrophin exons 71–74 in brain can
result in the removal of both syntrophin-binding motifs.
Moreover, regulating the stoichiometry of binding part-
ners using alternative splicing is likely to be a prominent
mechanism in modulating the signalling functions of other
large intracellular complexes.
The consequence of this flexibility in the number of syn-
trophin binding sites is likely to be reflected in the cellular
function of a particular dystrophin complex. In skeletal
muscle, the existence of four syntrophin-binding motifs
per DPC, which in theory may be occupied by any combi-
nation of four syntrophins (α, β1, β2 and γ2) [3,20], gener-
ates the potential for specialised complexes at different
locations and developmental stages (Figure 4). This may
be of particular importance in generating specific sig-
nalling complexes in synaptic versus extrasynaptic regions
of skeletal muscle fibres. Indeed, it is well documented
that the localisation of β2-syntrophin is restricted to the
postsynaptic membrane of the neuromuscular junction
[21], whereas β1-syntrophin expression is largely limited
to the sarcolemma of a subset of fast-twitch muscle fibres
(type IIB) [3]. Although the specificity of each syntrophin-
binding motif for a particular syntrophin is unknown, the
regulation of the number of syntrophin-binding sites
coupled with the extensive list of syntrophin-associated
proteins [4,25–28] is likely to be important in the con-
struction of specialised signalling complexes in muscle
and other tissues.
Materials and methods
H2K myotube cDNA library
H2K myoblasts [22] were differentiated in culture for 7 days into
myotubes before extraction of poly(A)+ RNA using FastTrack 2.0 (Invit-
rogen). cDNA was generated as described previously [5]. BstXI/EcoRI
adaptors were ligated onto cDNA ends and subsequently cloned into
the prey vector pYesTrp2 (Invitrogen).
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Figure 3
The syntrophin-binding motif of dystrobrevin binds syntrophin. The
western blot shown was probed with the pansyntrophin antibody
SYN1351 and demonstrates the specific purification of syntrophin from
brain extracts using an immobilised peptide corresponding to the
syntrophin-binding motif of dystrobrevin (SBM-PEP). An immobilised
control dystrobrevin peptide (DB-PEP) does not bind syntrophin nor
does the non-conjugated coupling gel alone (NO-PEP). 80 µg brain
RIPA extract is loaded in lane 1. The asterisks indicate IgG heavy and
light chains in the brain extract which can be detected using the HRP-
conjugated anti-mouse IgG secondary antibody alone. The absence of
IgG heavy chains in lane 2 negates the possibility of ‘spill over’ from
lane 1. Similar results were obtained using skeletal muscle extracts.
Molecular mass markers, in kDa, are indicated on the right.
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Figure 4
Revised model of the dystrophin protein complex in skeletal muscle.
The existence of two tandem syntrophin-binding motifs in
α-dystrobrevin and dystrophin generates four potential syntrophin-
binding sites in the DPC. The newly identified syntrophin-binding sites
are indicated in grey. Four potential syntrophin-binding proteins (ErbB4
receptor tyrosine kinase [25], voltage-gated sodium channel [26],
nNOS [4] and SAPK [27]) are shown which interact with the
syntrophin PDZ domain. An additional syntrophin-binding protein
microtubule-associated serine/threonine kinase 205 [28] is not shown.
Abbreviations: Syn, syntrophin; nNOS, neuronal nitric oxide synthase;
SAPK, stress-activated protein kinase-3; PDZ, PSD-95, Dlg and ZO-1
domain; CC, coiled-coil domain.
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Yeast two-hybrid analysis
All methods for yeast two-hybrid screening are described in the Hybrid
Hunter instruction manual (Invitrogen). The following α-dystrobrevin
baits were generated by PCR using the following primer sets and
cloned into the vector pHybLex/Zeo (Invitrogen): vr3 (forward:
5′-CAGAATTCTCAGGAAGTCCTTTCATCAC; reverse: 5′-CACTGA-
GTCACCGGTTTGAACTCTCA), exon 12 (forward: 5′-CAGAATTCT-
CTCCTCCCAAGGACAGTGA; reverse: 5’-CACTCGAGTCACCCT-
CTGCCCTTCAGAAA), exon 13 (forward: 5′-CAGAATTCGGGATAC-
AGTACAGCCTGAA; reverse: 5′-CACTCGAGTCATGGTGGGTTGT-
TCCGGA), exon 12 and 13 (exon 12 forward primer and exon 13
reverse primer), exon 14 and HI (forward: 5′-CAGAATTCATGCTTGA-
GAGTTCAAACCGG; reverse: 5′-CACTCGAGTCAGGGCTGGGA-
AGCTTGCT). The α- and β1-syntrophin preys were identified by
screening the H2K cDNA library with the vr3 bait. The β1-syntrophin
clone corresponds to nucleotides 1133–2158 (GenBank identifier
7710095) and the α-syntrophin clone corresponds to nucleotides
250–2012 (GenBank identifier 6678056). The yeast strain L40 was
transformed with appropriate baits and preys as indicated in Figure 1.
Individual co-transformants were streaked onto selective plates to test
for growth in the absence of histidine and onto permissive plates for
β-galactosidase filter assays. 
Peptide affinity chromotography
The syntrophin-binding motif peptide (SBM-PEP: NH2-RLDEE-HRLI-
ARYAARLAC) and a control dystrobrevin peptide (DB-PEP: NH2-CTGS-
PHTSPTHGGGRPM) were chemically coupled to SulfoLink Coulping
Gel (Pierce) according to the manufacturer’s instructions. Two hundred
microlitres of coupled SulfoLink gel was incubated overnight at 4°C with
2 mg of mouse brain or skeletal muscle extracted in RIPA buffer (150 mM
NaCl, 1% v/v Triton X-100, 0.5% w/v sodium deoxycholate, 0.1% w/v
SDS, 50 mM Tris pH 8.0) supplemented with protease inhibitors
(Sigma). The gel was washed extensively with RIPA buffer and eluted in
treatment buffer (3.8% w/v SDS, 4 M urea, 5% v/v β-mercaptoethanol,
20% v/v glycerol, 75 mM Tris pH 6.8). Samples were run on 10% poly-
acrylamide gels and western blotted according to standard methods.
Blots were probed with the pansyntrophin monoclonal antibody
SYN1351 and developed using the BM chemiluminescence substrate
system (Boehringer Mannheim).
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